SLP

Analyst Note: Simulations Plus, Inc. (SLP)

Date: 2026-06-20 Current Price: $18.24

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $18.24 Extension: — ATR at Breakout: — ATR Current: 4.6% (High) Pivot Strength: —

Setup Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None Named. Assessment: As of this date, SLP is not anchored to a named secular macro thesis. It is a tactical, setup-led name. Conviction must be derived strictly from the quality of the technical setup (the forming coil) and the underlying business fundamentals. There is no external narrative or sector-wide catalyst driving the thesis at this specific moment; the investment case rests entirely on the company's execution of its business model and the structural integrity of the price action.

3. Business Overview

Company Description: Simulations Plus, Inc. is a global provider of software and consulting services for the biopharmaceutical sector. The company enables clients to use modeling and simulation to accelerate drug development, reduce R&D costs, and comply with regulatory guidance.

Business Model & Segments: The company operates on a hybrid model of software licensing and professional services.

• Software: Represents the core recurring revenue engine. As of the fiscal year ended August 31, 2025, software accounted for 58% of total revenue. Key platforms include GastroPlus, MonolixSuite, ADMET Predictor, and Thales.
• Services: Represents 42% of revenue (FY2025), including development, adaptive learning solutions for clinical trials, and medical communications.

Operational Highlights (as of Q2 FY2026):

• Revenue Performance: In the second quarter ended April 9, 2026, the company delivered $24.3 million in revenue, exceeding top-line guidance. Growth was observed in both software and service segments.
• Backlog & Retention: Ending backlog increased 18% year-over-year to $24 million (from $20.4 million). The company reports 100% logo retention for top 20 pharma clients and 90% retention for companies with over $1 billion in global revenue.
• Strategic Pivot: In Q4 FY2025, the company pivoted to an account-based solution selling model, focusing on solving client pain points across the drug development lifecycle rather than selling discrete products.
• Financial Health: As of February 28, 2026, the company held $25.7 million in cash and cash equivalents, $16.1 million in short-term investments, and net working capital of $55.2 million.
• Margins: Overall gross margin improved to 66% for the three months ended February 28, 2026, up from 59% in the prior year period, driven by higher software/services mix, lower amortization, and higher billable utilization.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: SLP fits the Quality Compounder archetype due to its high retention rates, expanding backlog, and improving gross margins. The shift to an account-based model and the high stickiness of its software platforms (GastroPlus, etc.) suggest a compounding revenue base. The company is not a deep value recovery or a cyclical play; it is a structural growth story within the biopharma support ecosystem.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro tailwinds named).
• Evidence Quality: High. The earnings transcript (April 9, 2026) and SEC filings (April 10, 2026) provide clear, quantitative data on revenue beats, backlog growth, and margin expansion.
• Structural Quality: Moderate to High. The forming coil indicates a base is being built, but the breakout is pending. The "High" ATR (4.6%) suggests active interest but also volatility.
• Setup Readiness: Partial. The coil is forming, not confirmed.
• Rerating Potential: Dependent on the successful breakout of the forming coil and continued execution of the account-based sales model.

Valuation Context: Management guidance for Fiscal 2026 projects total revenue between $79 million and $82 million (0% to 4% YoY growth) and adjusted EBITDA margins between 26% to 30%. For Q3 2026, they anticipate revenue of $20 million to $22 million and adjusted diluted EPS of $0.20 to $0.27. The current price of $18.24 must be weighed against these guidance ranges and the company's cash position ($41.8M total liquid assets).

5. Invalidations, Strengths, and Gaps

Invalidation Triggers:

• Fundamental: A significant miss on the Q3 2026 guidance (specifically revenue below $20M or EPS below $0.20) or a sharp contraction in the backlog would undermine the "Quality Compounder" thesis.

Strengths:

• Backlog Growth: An 18% increase in backlog to $24 million provides near-term revenue visibility.
• Retention: 100% retention of top 20 clients demonstrates extreme product stickiness.
• Margin Expansion: Gross margin expansion to 66% indicates successful operational leverage and software mix shift.

Evidence Gaps:

• Specific Deal Values: While the transcript mentions a new program utilizing their platforms (E5), the specific financial terms or long-term takedown value of this new partnership are still "in discussion" (E7). The magnitude of this new revenue stream is not yet quantified.
• R&D Spend Trend: R&D costs rose to 18% of revenue for the six months ended Feb 28, 2026, compared to 13% the prior year (E11). While this may be strategic investment, the impact on near-term profitability is a variable to monitor.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) Q2 FY2026 revenue beat ($24.3M) with growth in both segments; 2) Backlog increased 18% YoY to $24M indicating strong demand; 3) Gross margin expanded to 66% driven by software mix and utilization. Key risks: 1) Technical setup is unconfirmed (forming coil, no breakout); 2) R&D costs as a % of revenue increased to 18% from 13%; 3) Lack of named secular thesis or macro catalyst. Sizing hint: Position size should be conservative given the unconfirmed technical setup and high ATR volatility. Expected path: Management expects Q3 revenue of $20M-$22M and EPS of $0.20-$0.27; if the forming coil breaks out, the stock may re-rate based on the account-based sales model execution. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation).